Category Archives: Manabu Ohyama

Brief Items of Interest, March 2017

Hair loss news first:

Replicel

— The biggest news this past month is from Canada based Replicel (Japan based Shiseido’s partner), a company that I have covered dozens of times on this blog before. They just released 5-year safety data for “a high-dose of dermal sheath cup cells (DSCC) for patients with pattern baldness due to androgenetic alopecia”, which is basically their RCH-01 product. Since the injected cells are a patient’s own cells (i.e., autologous), the positive safety results are not surprising. In regards to efficacy (on a small sample size of 19 test patients – > 10 male and 9 female): “an overall stabilization of hair loss was observed among all the patients treated per protocol”. The best 10 respondents witnessed a sustained 4.2 percent increase over baseline hair density at 24 months after injection. Will be interesting to see their 5-year post injection efficacy results, since current data only covered 2 years post injection results.

The scientists involved theorize that rather than one large dose, many small doses spread over some time period will result in even superior outcomes. Results will also improve as they learn more about optimum depth of injections, make use of their new proprietary injection device, and conduct gene expression analysis. FYI — I am much more interested in Shiseido than in Replicel, but unfortunately the former never makes any announcements (at least not in English newspapers), while the latter has in recent months been making a significant announcement almost every single week.

Dr. Manabu Ohyama

— I covered Dr. Manabu Ohyama on this blog before. This week he published an important study that could help advance research into overcoming the difficulties associated with the preparation of trichogenic human dermal papilla cells (and, as a result, help in the bioengineering of hair follicles). The study is too technical for me to understand without devoting many hours of time. However, I found it quite interesting that in the report, they devote a large section to Minoxidil. Interesting quote regarding how Minoxidil works:

“Minoxidil is a clinically used hair growth promoter that enhances hair KC (keratinocyte) proliferation and activates hDP cells to induce growth factors. IGF-1 is among these growth factors, and has been shown to exhibit a potent hair elongation effect.”

Cellmid

— I have covered Australian company Cellmid a few times on this blog before, usually very briefly since I am a skeptic about any purported benefits of their hair growth product beyond modest regrowth at best. However, today I read that the company’s CEO Maria Halasz purchased 400,000 shares of Cellmid (at a cost of $11,200) and now holds a total of 27.3 million shares. I guess either she really believes in their hair loss product (which inhibits fibroblast growth factor-5 = FGF-5), or she believes that she will be able to sell her stake at a higher price irrespective of how well the product ends up doing. The company has made several important announcements on Twitter recently, and saw phenomenal sales growth in the last quarter of 2016.

Aclaris Therapeutics update (h/t commentator “J_van”).

Interesting new video from hair transplant surgeon Dr. John Cole.

James Nesbitt and his hair transplants.

And now on to medical items of interest:

Terminal cancer remission in 1/3 of patients after new gene therapy treatment.

New blood test for early cancer detection.

Cambridge scientists create first self-developing embryo from stem-cells. In mice.

3D printed fully functional blood vessel network created via using an ultra-fast bioprinting system.

Interesting stem cell work from Japan/RIKEN (h/t commentator “baldings”).

Editas, Allergan and gene editing for eye diseases.

— Update on DIY biohacking:

Shiseido Discusses Replicel Technology

The below two superb videos from Japan’s Shiseido were shared by its Canadian partner Replicel three weeks ago. I delayed embedding them here until they had English subtitles (which they now do if you click on CC in the lower right corner of the videos). Some of the visuals are very interesting and instructive. In my opinion, if final clinical trials this year work out as expected, Shiseido will be able to bring this technology to fruition far more rapidly and easily in comparison to Replicel due to two main reasons:

  1. Japan’s newer much more friendlier regulations governing regenerative medicine and stem cell research.  Stage 3 clinical trials will no longer be required in Japan.
  2. Shiseido’s drastically larger size and funding availability in comaprison to Replicel.  According to wikipedia, Shiseido is the largest cosmetics firm in Japan, and the fourth largest cosmetics firm in the world.

The second video covers the work of Dr. Takashi Tsuji and of Dr. Manabu Ohyama (who it seems might be working for Shiseido).